NeOnc Reports Early Improvement in Compassionate-Use Patient

Treating physicians observed early improvement in a 3-year-old with an aggressive brain tumor receiving investigational intranasal NEO100 through compassionate use in Abu Dhabi. The company said the anecdotal finding is not evidence of safety or efficacy.